First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Green3Bio, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04711161
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath